According to Zoll, the WEARIT-II registry includes more than 2,000 patients prescribed the LifeVest wearable defibrillator. Advice module 734 can include a Shock Advisory Algorithm, implement decision rules, and so on. The advice can be to shock, to not shock, to administer other forms of therapy, and so on. If the advice is to shock, some external defibrillator embodiments merely report that to the user, and prompt them to do it. Other embodiments further execute the advice, by administering the shock.
The only randomised controlled trial investigating its use to date is the VEST trial 6 It failed to show a significant reduction ZOLL LifeVest Wearable Defibrillator in arrhythmic death in patients with severely reduced EF during the early post-myocardial infarction phase with use of the WCD.
39. Unknown Cardiac Prognosis Use of WCDs may be reasonable when there is concern about a heightened risk of SCD that may resolve over time or treatment of left ventricular dysfunction, for example, in ischemic heart disease with recent revascularization, newly diagnosed nonischemic dilated cardiomyopathy in a patient starting guideline-directed medical therapy, or secondary cardiomyopathy (tachycardia mediated, thyroid mediated, etc) in which the underlying cause is potentially treatable (Class IIb; Level of Evidence C) 39 Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death.
For example, patients who have had large myocardial infarctions or undergone coronary revascularization with decreased left ventricular function (LVEF ++<++ 30%) may be candidates for ICD implantation if their ventricular function does not improve after 1 or 3 months, respectively (MADIT-2 criteria).
If the first set of defibrillation waveforms delivered across the first set of vectors fail to establish a regular heart rhythm in the patient, the defibrillator circuit has the capability to deliver a second set of defibrillation waveforms across the second set of vectors.
44. Recommendation Use of WCDs is reasonable as a bridge to more definitive therapy such as cardiac transplantation (Class IIa; Level of Evidence C) 44 Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death.
However, in an as-treated analysis, a significantly lower percentage of patients died when they were wearing the wearable cardioverter-defibrillator than when they were not, a finding that remained significant even after the most conservative correction for multiple comparisons.
27. Clinical Experience With WCDs Newly diagnosed cardiomyopathy, NYHA class IV heart failure, and those for transplantation 42% experienced recovery and did not develop an indication for permanent ICD None of the patients had SCD or required WCD therapy Event rates lower in patients with newly diagnosed cardiomyopathy (<1%) Event rates are also lower in patients with recent revascularization Although overall event rates are lower in patients with newly diagnosed cardiomyopathy or recent coronary revascularization, retrospective observational data suggest that the WCD may confer a survival benefit 27 Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death.
Blog Search
Blog Archive
- February 2021 (50)
- January 2021 (48)
- December 2020 (47)
- November 2020 (46)
- October 2020 (40)
- September 2020 (51)
- August 2020 (49)
- July 2020 (61)
- June 2020 (66)
- May 2020 (70)
- April 2020 (70)
- March 2020 (77)
- February 2020 (84)
- January 2020 (80)
- December 2019 (74)
- November 2019 (77)
- October 2019 (76)
- September 2019 (62)
- August 2019 (75)
- July 2019 (82)
- June 2019 (63)
- May 2019 (75)
- April 2019 (62)
- March 2019 (52)
- February 2019 (40)
- January 2019 (41)
- December 2018 (39)
Comments
There are currently no blog comments.